DPY30

Across TCGA pan-cancer cohorts, DPY30 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DPY30 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher DPY30 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DPY30 expression acts as an unfavorable survival marker.

STAD are the cancer types where DPY30 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.183	0.677	.004	24	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

DPY30–STAD (OS)

Open the STAD breakdown →